En DE FR ES PL
Interactive - instructions for use, testimonials, analogs and forms of release (injections in ampoules for injections 500 thousand IU, 1 million IU, 3 million IU and 5 million IU P) of a drug for the treatment of hepatitis and leukemia in adults, children and during pregnancy. Composition

Interactive - instructions for use, testimonials, analogs and forms of release (injections in ampoules for injections 500 thousand IU, 1 million IU, 3 million IU and 5 million IU P) of a drug for the treatment of hepatitis and leukemia in adults, children and during pregnancy. Composition

In this article, you can read the instructions for using the drug Interactive. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on using Interal in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Inter Analogues in the presence of existing structural analogs. Use to treat viral hepatitis and leukemia in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

 

Interactive - a drug with antiviral, antitumor, immunomodulating activity. Antiviral action is due to interaction with specific membrane receptors and induction of RNA synthesis and, ultimately, proteins. The latter, in turn, interfere with the normal reproduction of the virus or its release. Immunomodulating activity is associated with activation of phagocytosis, stimulation of the formation of antibodies and lymphokines. Interval has an antiproliferative effect on tumor cells. The drug, like all interferons, can lead to the appearance of specific antibodies, which leads to a decrease in its therapeutic effect.

 

Composition

 

Interferon alfa-2a + auxiliary substances.

 

Pharmacokinetics

 

Time of the maximum concentration of interferon-alpha after intramuscular injection is 2 hours, and it lasts up to 12 hours, after subcutaneous administration - 7.3 hours, after 20 hours the drug is not detected. The half-life with intramuscular injection is about 2-3 hours. Bioavailability - 80%. The drug is evenly distributed to organs and tissues. Biotransformed in the kidneys and to a small extent in the liver.It is partially excreted unchanged, mainly through the kidneys.

 

Indications

  • acute hepatitis B;
  • chronic hepatitis B;
  • chronic hepatitis C;
  • viral (influenza, adenovirus, enterovirus, herpetic, parotitic), viral-bacterial and mycoplasmal meningoencephalitis;
  • stromal keratitis and keratoiridocyclitis (inflammation of the cornea, iris, ciliary body);
  • keratoacanthoma (benign skin tumor);
  • acute lymphoblastic leukemia in the period of remission;
  • hairy cell leukemia;
  • chronic myelogenous leukemia;
  • renal cell carcinoma (kidney cancer);
  • Kaposi's sarcoma against AIDS;
  • basal cell and squamous cell carcinoma;
  • cutaneous T-cell lymphoma (mushroom mycosis and Cesari syndrome);
  • malignant melanoma (skin cancer);
  • histiocytosis-X (anomalies of cells-histiocytes with unknown etiology);
  • essential thrombocythemia (tumor blood disease);
  • Multiple sclerosis (autoimmune disease with nerve fiber damage);
  • respiratory papillomatosis of the larynx.

 

Forms of release

 

Lyophilizate for solution for injection (injections in ampoules) 500 thousand IU, 1 million IU, 3 million IU and 5 million IU (InterPal).

 

Other dosage forms, whether candles or tablets, at the time of publication of the drug in the Directory did not exist.

 

Instructions for use and dosing regimen

 

The intramuscular, intramuscular, or lesion is subcutaneously injected, subconjunctivally. Immediately before use, the contents of the ampoule are dissolved in water for injection (1 ml for intramuscular administration and introduction into the focus, 5 ml for subconjunctival administration). The dissolution time is not more than 3 minutes. The drug solution should be transparent, without foreign inclusions. The diluted drug is not subject to storage.

 

Intramuscular injection

 

In acute hepatitis B, 1 ml of ME is administered 2 times a day for 5-6 days, then the dose is reduced to 1 million IU per day and injected for another 5 days. If necessary (after the control biochemical blood tests), the treatment course can be continued 1 million ME 2 times a week for 2 weeks. The course dose is 15-21 million ME.

 

In acute prolonged and chronic active hepatitis B, with the exception of delta infection and without signs of hepatic cirrhosis, 1 ml of ME is injected intravenously twice a week for 1-2 months. In the absence of the effect, the treatment should be extended to 3-6 months or after the end of the 1-2-month treatment, 2-3 similar courses should be performed at intervals of 1-6 months.

 

In chronic active hepatitis D without signs of liver cirrhosis, the drug is administered 500,000 to 1 million ME per day 2 times a week for 1 month. Repeated course of treatment after 1-6 months.

 

With chronic active hepatitis B and D with signs of cirrhosis of the liver for 250-500 thousand ME per day 2 times a week for 1 month. When there are signs of decompensation, similar repeated courses are conducted with an interval of at least 2 months.

 

In chronic hepatitis C, Interal monotherapy is administered subcutaneously to 3 million IU once a day every other day for 24 weeks or combined therapy with ribavirin. In case of recurrence of the disease after the course of monotherapy with interferon, the repeated course should be performed in combination with Ribavirin for at least 6 months. In patients who do not have RNA of hepatitis C virus (HCV RNA) by the end of the first 6 months of therapy in the blood serum, the treatment is continued for another 6 months.

 

In chronic hepatitis C in children, monotherapy (excluding patients with the 1b genotype of the virus) of 3 million IU per square meter of body surface area is recommended, but not more than 3 million IU three times a week, or combination therapy with antiviral drugs for 12 months .In the absence of an early virologic response with monotherapy (after 3 months), it is necessary to switch to combination therapy.

 

In case of cancer of the kidney, Intral is used for 3 million IU daily for 10 days. Repeated courses of treatment (3-9 or more) are carried out at intervals of 3 weeks. The total amount of the drug is from 120 million ME to 300 million ME or more.

 

With hairy cell leukemia, Enteral is administered daily for 3-6 million ME for 2 months. After the normalization of the hemogram, the daily dose of Interal is reduced to 1-2 million IU. Then support therapy is prescribed for 3 million ME 2 times a week for 6-7 weeks. The total amount of the drug is 420-600 million ME or more.

 

In acute lymphoblastic leukemia in children in remission after the end of inductive chemotherapy (at the 4-5 month of remission), 1 million ME once a week for 6 months, then 1 every 2 weeks for 24 months. Simultaneously, supportive chemotherapy is performed.

 

In chronic myelogenous leukemia, 3 million ME daily or 6 million ME every other day. The treatment period is from 10 weeks to 6 months.

 

With histiocytosis-X, 3 million IU daily for 1 month. Repeated courses with 1-2-month intervals for 1-3 years.

 

With subleukemic myelosis and essential thrombocytopenia for correction of hyperthrombocytosis by 1 million.ME daily or after 1 day for 20 days.

 

In malignant lymphomas and sarcoma of Kaloshi, Interal is administered 3 million IU per day daily for 10 days in combination with cytostatics (prospidin, cyclophosphamide) and glucocorticosteroids.

 

In the tumor stage of fungal mycosis and reticulosarcomatosis, it is advisable to alternate intramuscular injection of Interal by 3 million ME and intraocular injection of 2 million ME for 10 days. In patients with erythrodermic stage of fungal mycosis with an increase in temperature above 39 degrees and in case of aggravation of the process, the drug should be discontinued. In case of insufficient therapeutic effect, after 10-14 days a second course of treatment is prescribed. After achieving a clinical effect, a maintenance therapy of 3 million IU is prescribed once a week for 6-7 weeks.

 

With respiratory papillomatosis of the larynx, the drug is administered for 100-150 thousand IU per 1 kg of body weight daily for 45-50 days, then in the same dosage 3 times a week for 1 month. The second and third courses are conducted at intervals of 2-6 months.

 

With multiple sclerosis, Intral is prescribed for 1 million ME: for pyramidal syndrome 3 times a day, for cerebellar syndrome 1-2 times per day for 10 days followed by 1 million IU once a week for 5-6 months .The total amount of the drug is 50-60 million ME.

 

Perifocal administration

 

In basal cell and squamous cell carcinoma, keratoacanthoma, the virus is injected under the lesion 1 million IU once daily for 10 days. In the case of pronounced local inflammatory reactions, the injection under the lesion is carried out after 1-2 days. At the end of the course, if necessary, conduct a cryodestruction.

 

Subconjunctival administration

 

In stromal keratitis and keratoiridocyclitis, intra-conjunctival injections of Interal are administered at a dose of 60,000 IU in a volume of 0.5 ml daily or every other day, depending on the severity of the process. Injections are performed under local anesthesia with a 0.5% solution of dicain. The course of treatment for 15 to 25 injections.

 

Side effect

  • fever;
  • chills;
  • pain in bones, joints;
  • Myalgia (pain in the muscles);
  • headache;
  • dizziness;
  • increased sweating;
  • nausea, vomiting;
  • diarrhea;
  • decreased appetite;
  • constipation;
  • a violation of taste sensations;
  • dry mouth;
  • decrease in body weight;
  • mild pain in the abdomen;
  • small changes in liver function indicators (usually normalized after the end of treatment);
  • deterioration of mental activity;
  • disturbance of sleep and memory;
  • anxiety, nervousness, aggression;
  • euphoria or depression;
  • neuropathy (pathology of nerve fibers);
  • tremor (involuntary trembling of fingers);
  • propensity to commit suicide (in some cases);
  • arrhythmia (tachycardia with fever);
  • hypertension or hypotension;
  • ischemic heart disease and myocardial infarction;
  • pain in the chest, cough;
  • slight shortness of breath;
  • pneumonia (pneumonia);
  • pulmonary edema;
  • leukopenia (decrease in the number of leukocytes in the blood);
  • thrombocytopenia (decrease in the number of platelets in the blood);
  • granulocytopenia (decrease in granulocyte content in the blood);
  • itching;
  • reversible alopecia (baldness);
  • muscular stiffness;
  • conjunctivitis (inflammation of the conjunctiva of the eye);
  • inflammation at the injection site;
  • antibodies to natural or recombinant interferons.

 

Contraindications

  • severe cardiovascular diseases;
  • decompensated cirrhosis of the liver;
  • severe depression;
  • psychosis;
  • alcohol or drug dependence;
  • hypersensitivity to the components of the drug;
  • autoimmune diseases;
  • chronic renal failure 2-3 degrees.

 

Application in pregnancy and lactation

 

Use in pregnancy is possible only if the intended benefit of therapy for the mother exceeds the potential risk to the fetus.

 

It is not known whether Interferon alpha is excreted in breast milk. If it is necessary to use during the lactation period, the question of stopping breastfeeding should be solved.

 

Women of childbearing age in the period of treatment should use reliable contraception.

 

Use in children

 

Interval is used in complex therapy in children:

  • with acute lymphoblastic leukemia in remission after the end of inductive chemotherapy (at 4-5 months of remission);
  • with respiratory papillomatosis of the larynx, starting from the next day after removal by papillomas;
  • with chronic active hepatitis C in children, starting with three years, in monotherapy and combination therapy with antiviral drugs.

 

Application in elderly patients

 

With the development of side effects from the central nervous system in elderly patients receiving interferon alfa in high doses, a thorough examination should be conducted and, if necessary, interrupted treatment.

 

special instructions

 

Use with caution in patients with impaired renal, hepatic, and bone marrow hematopoiesis, with a tendency to suicidal attempts.

 

Patients with diseases of the cardiovascular system may have arrhythmia. If the arrhythmia does not decrease or increases, the dose should be reduced 2 times, or stop treatment.

 

During the period of treatment, control of the neurological and mental status is necessary.

 

With severe oppression of bone marrow hematopoiesis, a regular study of the composition of peripheral blood is necessary.

 

Interferon alfa has a stimulating effect on the immune system, so it should be used with caution in patients prone to autoimmune diseases, because of the increased risk of autoimmune reactions.

 

In individuals with a high pyrogenic reaction (39 degrees and above), it is recommended to inject the IV together with Indomethacin.

 

Drug Interactions

 

Interferon, like all interferons, can reduce the activity of P-450 liver cytochromes and, therefore, interfere with metabolism and decrease the rate of elimination of theophylline, cimetidine, phenytoin, quarantil, diazepam, propranolol, warfarin, and some cytostatics, which should be taken into account when dosing.

 

Also, Intel enhances the phosphorylation of ribavirin, causing synergism of the antiviral effect, therefore, it is prescribed with it in complex therapy.

 

Interference can enhance neurotoxic, myelotoxic or cardiotoxic effects of drugs administered earlier or simultaneously with it.

 

It should avoid joint use with drugs that depress the central nervous system, immunosuppressive drugs (including corticosteroids).

 

Analogues of Drug Interval

 

Structural analogs for the active substance:

  • Algeron;
  • Altevir;
  • Alfaron;
  • Alfaferon;
  • Vagiphereon;
  • Viferon;
  • Wallferon;
  • Genferon;
  • Herpferon;
  • Hyaferon;
  • Grippferon;
  • Intrinsic P;
  • Interferal;
  • Intron A;
  • Infagel;
  • Inferon;
  • Layfferon;
  • Lokferon;
  • Ophthalmoferon;
  • Reaferon-EU-Lipint;
  • Roferon A.

 

Doctor's Feedbackinfectious disease

 

Preparations based on interferon-alpha have proven themselves in the treatment of chronic viral hepatitis. Their advantage in ability in parallel with the increase in the resistance of the immune system to the virus inhibits the proliferation of liver cells. Thus, interferon also prevents the development of cirrhosis and liver cancer, which often complicate hepatitis C.The main drawback of interferon-alpha preparations, including Interal, is the mass of side effects, including chronic fatigue and depression, down to suicide. In this regard, I often prescribe to patients drugs based on pegylated interferon, although they are not affordable for everyone.

 

Similar medicines:

Other medicines:

Reviews (0):

Rules for publishing reviews and visitor questions